Dr. Mohit (Mo) Trikha is CEO of Kivu Bioscience and brings more than 25 years of oncology drug development experience. He has helped advance more than 40 oncology programs from discovery through clinical development. Prior to Kivu, he was a venture partner at Apple Tree Partners and led oncology early development at AbbVie, focusing on ADCs, bispecific antibodies, and CAR-T therapies. Trikha has contributed to the development of Kadcyla, Polivy, and vismodegib, and holds a PhD in Biochemistry and Molecular Biology from the University of Southern California.
At the BIO International Convention 2026, oncology drug development expert Mohit Trikha, PhD, CEO, Kivu Bioscience, discusses the promise and limitations of organoids and other human-based preclinical models, emphasizing the need for stronger validation, cross-functional collaboration, and early regulatory engagement to improve clinical trial success rates.
